|
2026 Journal Article Varenicline for the management of cannabis use disorder: a systematic reviewCraig, Courtney, Waldmann, Jana, Daglish, Mark, Connor, Jason P. and Parker, Stephen (2026). Varenicline for the management of cannabis use disorder: a systematic review. Journal of Substance Use and Addiction Treatment, 191 210090, 1-9. doi: 10.1016/j.josat.2026.210090 |
|
2026 Journal Article General practitioner management of adult ADHD: Challenges and implicationsJohnson, Benjamin, Parker, Stephen, Hall, Wayne, Leung, Janni and Chan, Gary (2026). General practitioner management of adult ADHD: Challenges and implications. Australasian Psychiatry 10398562261502219. doi: 10.1177/10398562261502219 |
|
2026 Journal Article Moving towards evidence-based screening and investigations in first episode psychosis: A commentary on the ANZJP GRADE Schizophrenia GuidelinesChalmers, Kirk, Laurie, Kirsty, Nitz, Megan, Debattista, Joseph and Parker, Stephen (2026). Moving towards evidence-based screening and investigations in first episode psychosis: A commentary on the ANZJP GRADE Schizophrenia Guidelines. Australian & New Zealand Journal of Psychiatry 00048674261497851. doi: 10.1177/00048674261497851 |
|
2026 Journal Article Optimal drug, dose and duration of antipsychotic therapy following amphetamine and cannabis-induced psychosis: A systematic reviewHall, Edward, Ratnayake, Nisitha, Waldmann, Jana, Daglish, Mark, Scott, James G., Connor, Jason P. and Parker, Stephen (2026). Optimal drug, dose and duration of antipsychotic therapy following amphetamine and cannabis-induced psychosis: A systematic review. Australian & New Zealand Journal of Psychiatry 00048674261490027. doi: 10.1177/00048674261490027 |
|
2026 Journal Article The risk of psychosis associated with cannabis use by people with attention-deficit hyperactivity disorder: a systematic reviewSuetani, Shuichi, Honarparvar, Faraz, Muller, Peter, Kesby, James P. and Parker, Stephen (2026). The risk of psychosis associated with cannabis use by people with attention-deficit hyperactivity disorder: a systematic review. Australasian Psychiatry, 10398562261439662. doi: 10.1177/10398562261439662 |
|
2026 Journal Article Psychiatrists’ and psychiatry trainees’ perspectives of treatment priorities and the role of cognitive symptoms in supporting people with psychotic disordersKesby, James P., Suetani, Shuichi, Sleight, Isabella, Wood, Jessica C., Trott, Mike, McKeon, Gemma, Dark, Frances and Parker, Stephen (2026). Psychiatrists’ and psychiatry trainees’ perspectives of treatment priorities and the role of cognitive symptoms in supporting people with psychotic disorders. Australian & New Zealand Journal of Psychiatry 00048674261480588, 48674261480588. doi: 10.1177/00048674261480588 |
|
2026 Journal Article Commentary on the ANZJP Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines for the management of schizophrenia – where are the recommendations for methamphetamine-related psychoses?Galletly, Cherrie, Arunogiri, Shalini, Hall, Edward, Parker, Stephen, Sara, Grant and Lappin, Julia (2026). Commentary on the ANZJP Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines for the management of schizophrenia – Where are the recommendations for methamphetamine-related psychoses?. Australian & New Zealand Journal of Psychiatry 00048674261475184. doi: 10.1177/00048674261475184 |
|
2026 Journal Article Meeting family education and support needs in the early psychosis context: description and evaluation of a pragmatic family programHolland, Melissa, Parker, Stephen, Sanders, Naomi, Flear, Joanne, Clarkson, Tessa and Burke, Kylie (2026). Meeting family education and support needs in the early psychosis context: description and evaluation of a pragmatic family program. Early Intervention in Psychiatry, 20 (8) e70228. doi: 10.1111/eip.70228 |
|
2026 Journal Article The challenge of improving assessment and treatment for attention-deficit/hyperactivity disorder in AustraliaJohnson, Benjamin, Parker, Stephen, Xu, Richard, Simmons, Rachel and Hall, Wayne (2026). The challenge of improving assessment and treatment for attention-deficit/hyperactivity disorder in Australia. Australian and New Zealand Journal of Psychiatry, 48674261465180. doi: 10.1177/00048674261465180 |
|
2026 Journal Article Letter to the Editor regarding 'Australian and New Zealand Journal of Psychiatry Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines for the management of schizophrenia'Purushothaman, Subramanian, Kolur, Uday, Ketheesan, Sarangan, Parthasarathy, Bhargavaraman, Stark, Anne, Sawhney, Vinit and Parker, Stephen (2026). Letter to the Editor regarding 'Australian and New Zealand Journal of Psychiatry Grading of Recommendations, Assessment, Development and Evaluations (GRADE) guidelines for the management of schizophrenia'. The Australian and New Zealand Journal of Psychiatry 00048674261470984. doi: 10.1177/00048674261470984 |
|
2026 Journal Article Diagnostic complexities of autism and psychosis: A commentary on the ANZJP GRADE guidelines for the management of schizophreniaChalmers, Kirk, Laurie, Kirsty, Suetani, Shuichi, Franklin, Catherine, Scott, James G and Parker, Stephen (2026). Diagnostic complexities of autism and psychosis: A commentary on the ANZJP GRADE guidelines for the management of schizophrenia. Australian and New Zealand Journal of Psychiatry, 48674261461986. doi: 10.1177/00048674261461986 |
|
2026 Journal Article Cardiovascular risk factors and serious health events in individuals with eating disorders: a systematic reviewMurphy, Kate E., Sidari, Morgan J., Skerlj, Thomas A., McMahon, Kirsten L., Parker, Stephen, Pearson, Chloe, Waldmann, Jana Y. and Eggins, Elizabeth (2026). Cardiovascular risk factors and serious health events in individuals with eating disorders: a systematic review. Journal of Eating Disorders. doi: 10.1186/s40337-026-01691-x |
|
2026 Journal Article Intramuscular clozapine: a systematic scoping review of clinical feasibility, safety, and efficacyDhaliwal, Noori, Kaladharan, Sid, Waldmann, Jana, Siskind, Dan and Parker, Stephen (2026). Intramuscular clozapine: a systematic scoping review of clinical feasibility, safety, and efficacy. Journal of Clinical Psychopharmacology, 46 (5), 625-635. doi: 10.1097/jcp.0000000000002198 |
|
2026 Journal Article ‘Domo arigato, Mr Roboto’: artificial intelligence and psychiatry from the laggards’ perspectiveSuetani, Shuichi, Budgen, Jordan and Parker, Stephen (2026). ‘Domo arigato, Mr Roboto’: artificial intelligence and psychiatry from the laggards’ perspective. The British Journal of Psychiatry, 229 (2) PMID 342367, 1-2. doi: 10.1192/bjp.2026.10545 |
|
2026 Journal Article Predictors of engagement in community-based residential mental health rehabilitation: Modelling of a cross-sectional statewide benchmarking dataset from Queensland, AustraliaFalvey, Olivia, Jones, Donna, Stedman, Terry and Parker, Stephen (2026). Predictors of engagement in community-based residential mental health rehabilitation: Modelling of a cross-sectional statewide benchmarking dataset from Queensland, Australia. Community Mental Health Journal, 62 (1), 166-176. doi: 10.1007/s10597-025-01512-6 |
|
2025 Journal Article Development of an Australian clinical practice guideline on methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorderYong, Alene Sze Jing, Brennan, Sue E., Bratuskins, Suzie, Freeburn, Aimee, Bedi, Gillinder, Burke, Rimona, Hollick, Mary, Jones, Kimberley Ann, Lawrence, Andrew J., Lee, Yong Yi, McFarlane, Alexander C., Parker, Stephen, Procter, Nicholas, Spicer, Liam, Somogyi, Andrew A., Stafrace, Simon, Watts, Stacey, Walton, Clare, Wilson, Kay and Bell, J. Simon (2025). Development of an Australian clinical practice guideline on methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder. Journal of Affective Disorders, 391 119866, 1-10. doi: 10.1016/j.jad.2025.119866 |
|
2025 Journal Article Long-term neurocognitive side effects of MDMA in recreational ecstasy users following sustained abstinence: a systematic review and meta-analysisUng, Hillary, McKeon, Gemma, Jokovic, Zorica, Parker, Stephen, Vickers, Mark, Malacova, Eva, Eriksson, Lars and Daglish, Mark (2025). Long-term neurocognitive side effects of MDMA in recreational ecstasy users following sustained abstinence: a systematic review and meta-analysis. Journal of Psychopharmacology, 40 (2) 02698811251389559, 2698811251389559-285. doi: 10.1177/02698811251389559 |
|
2025 Journal Article Comparison of cognitive screening tools used to assess neurocognitive side effects of electroconvulsive therapy: a systematic reviewDodd, Jeremy, Brown, Emma, Eriksson, Lars, Garrett-Walcott, Simone, Purushothaman, Subramanian, Martin, Donel, Parker, Stephen and Vickers, Mark (2025). Comparison of cognitive screening tools used to assess neurocognitive side effects of electroconvulsive therapy: a systematic review. The Journal of ECT, 1-9. doi: 10.1097/yct.0000000000001181 |
|
2025 Journal Article Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providersNadeem, Zohaib, Parker, Stephen, McGovern, Hugh, Sebben, Bianca and Oestreich, Lena K. L. (2025). Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers. Australian and New Zealand Journal of Psychiatry, 59 (9) 00048674251346679, 798-809. doi: 10.1177/00048674251346679 |
|
2025 Journal Article Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in AustraliaSiskind, Dan, Baker, Andrea, Arnautovska, Urska, Warren, Nicola, Russell, Anthony, DeMonte, Veronica, Halstead, Sean, Iyer, Ravi, Korman, Nicole, McKeon, Gemma, Medland, Sarah, Parker, Stephen, Stedman, Terry and Trott, Mike (2025). Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia. The Lancet Psychiatry, 12 (7), 493-503. doi: 10.1016/S2215-0366(25)00129-4 |
